ArticleJournal of enzyme inhibition and medicinal chemistry2023

Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.

Seohyun Son et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.